VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology, LLC
VM Oncology, LLC
Incyte Corporation
NuCana plc
Medicenna Therapeutics, Inc.
NGM Biopharmaceuticals, Inc
Rain Oncology Inc
Incyte Corporation
Incyte Corporation